Literature DB >> 26502403

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

Chul Kim1, Vinay Prasad2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26502403     DOI： 10.1001/jamainternmed.2015.5868

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  90 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  ADAURA: Mature Enough for Publication, Not for Prime Time.

Authors:  Alfredo Addeo; Giuseppe Luigi Banna; Alex Friedlaender
Journal:  Oncologist       Date:  2020-12-24

3.  A Major Shortcoming in the Public Health Legacy of the Obama Administration.

Authors:  Diana M Zuckerman
Journal:  Am J Public Health       Date:  2017-01       Impact factor: 9.308

4.  Acute myeloid leukemia therapy and the chosen people.

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

5.  The race for drug approvals: hasten slowly?

Authors:  Alain Braillon
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

6.  Real-World Evidence: Promise and Peril For Medical Product Evaluation.

Authors:  Sanket S Dhruva; Joseph S Ross; Nihar R Desai
Journal:  P T       Date:  2018-08

7.  When Will Presidential Candidates Ask, "What Do Women Want in Health Care?".

Authors:  Diana Zuckerman
Journal:  Am J Public Health       Date:  2016-05       Impact factor: 9.308

8.  Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies.

Authors:  Oriana Ciani; Bogdan Grigore; Hedwig Blommestein; Saskia de Groot; Meilin Möllenkamp; Stefan Rabbe; Rita Daubner-Bendes; Rod S Taylor
Journal:  Med Decis Making       Date:  2021-03-10       Impact factor: 2.583

Review 9.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Authors:  Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

10.  Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.

Authors:  Narcyz Ghinea; Miles Little; Wendy Lipworth
Journal:  J Bioeth Inq       Date:  2017-07-18       Impact factor: 1.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.